Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.

Hdl Handle:
http://hdl.handle.net/10144/17283
Title:
Cotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.
Authors:
Zachariah, R; Massaquoi, M
Journal:
Tropical Doctor
Abstract:
Despite provisional recommendations from the World Health Organization and UNAIDS that cotrimoxazole (CTX) prophylaxis be offered to all individuals living with AIDS, including HIV-positive patients with TB, its routine use in developing countries particularly Africa has been minimal. Concerns were expressed regarding its effectiveness in areas of high bacterial resistance, that its widespread use might substantially increase bacterial cross-resistance in the community and that this intervention might promote resistance of malaria parasites to sulphadoxine-pyrimethamine. We review the current evidence on the above concerns and highlight the main operational considerations related to implementing CTX prophylaxis as a basic component of care for HIV-positive TB patients in developing countries.
Affiliation:
Medecins sans Frontieres, Operational Research HIV-TB, Medical department, Brussels Operational Center, 68 Rue de Gaspench, L-1617 Luxemburg. zachariah@internet.lu
Issue Date:
Apr-2006
URI:
http://hdl.handle.net/10144/17283
DOI:
10.1258/004947506776593314
PubMed ID:
16611438
Additional Links:
http://td.rsmjournals.com
Language:
en
ISSN:
0049-4755
Appears in Collections:
HIV/AIDS

Full metadata record

DC FieldValue Language
dc.contributor.authorZachariah, R-
dc.contributor.authorMassaquoi, M-
dc.date.accessioned2008-01-31T16:19:21Z-
dc.date.available2008-01-31T16:19:21Z-
dc.date.issued2006-04-
dc.identifier.citationCotrimoxazole prophylaxis for HIV-positive TB patients in developing countries. 2006, 36 (2):79-82notTrop Doct-
dc.identifier.issn0049-4755-
dc.identifier.pmid16611438-
dc.identifier.doi10.1258/004947506776593314-
dc.identifier.urihttp://hdl.handle.net/10144/17283-
dc.description.abstractDespite provisional recommendations from the World Health Organization and UNAIDS that cotrimoxazole (CTX) prophylaxis be offered to all individuals living with AIDS, including HIV-positive patients with TB, its routine use in developing countries particularly Africa has been minimal. Concerns were expressed regarding its effectiveness in areas of high bacterial resistance, that its widespread use might substantially increase bacterial cross-resistance in the community and that this intervention might promote resistance of malaria parasites to sulphadoxine-pyrimethamine. We review the current evidence on the above concerns and highlight the main operational considerations related to implementing CTX prophylaxis as a basic component of care for HIV-positive TB patients in developing countries.-
dc.language.isoen-
dc.relation.urlhttp://td.rsmjournals.com-
dc.rightsReproduced on this site with the permission of Royal Society of Medicine Press, London (www.rsmpress.co.uk/td.htm)en_GB
dc.subject.meshAIDS-Related Opportunistic Infections-
dc.subject.meshAdult-
dc.subject.meshAfrica South of the Sahara-
dc.subject.meshAnti-Infective Agents-
dc.subject.meshChild-
dc.subject.meshDrug Resistance-
dc.subject.meshHumans-
dc.subject.meshMalaria-
dc.subject.meshTrimethoprim-Sulfamethoxazole Combination-
dc.subject.meshTuberculosis-
dc.titleCotrimoxazole prophylaxis for HIV-positive TB patients in developing countries.-
dc.contributor.departmentMedecins sans Frontieres, Operational Research HIV-TB, Medical department, Brussels Operational Center, 68 Rue de Gaspench, L-1617 Luxemburg. zachariah@internet.lu-
dc.identifier.journalTropical Doctor-

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.